


# COVID-19 KP.2 Immunization Program Fall 2024



September 2024

# Introduction

On completion of this presentation the learner will understand the clinical information update for the fall 2024 COVID-19 KP.2 Immunization Program.

Operational questions will NOT be addressed during this presentation (i.e., vaccine distribution specifics).

Always use the online resources for the most up to date information.

# Introduction

For more detailed information it is important for staff to refer to other program resources found on the Alberta Health Services (AHS) websites and orientation presentations such as:

- COVID-19 Health Professional Immunization webpage
- AHS Vaccine Biological pages and/or Vaccine Product Monographs
- AHS Vaccine Storage and Handling e-learning modules and Standard
- Guidelines for the reporting of Adverse Events Following Immunization(AEFI)
- Vaccine Administration
- Reporting requirements and data collection guidelines
- Alberta Immunization Policy: Alberta Outreach Immunization Program

# COVID-19 Vaccines Available in Alberta

- mRNA
  - Moderna (Spikevax) KP.2 Frozen Vaccine
  - Pfizer (Comirnaty) KP.2 Ultra Frozen Vaccine



## Those at increased risk of transmission or severe COVID-19 infection

While all individuals 6 months of age and older are eligible for COVID-19 vaccine, immunization is strongly recommended for the following individuals who may be at an increased risk of COVID-19 infection or severe COVID-19 disease:

- Individuals 65 years of age and older
- Individuals 6 months of age and older
  - Residents of continuing care homes and senior supportive living accommodations.
  - Have certain moderate to severe immunocompromising conditions.
  - Pregnant
  - First Nations, Métis, and Inuit individuals, including First Nations no matter where they live.
  - Members of racialized and other equity deserving populations.
  - People who provide essential community services, including healthcare workers

# Moderna mRNA COVID-19 Vaccine Summary

	Moderna COVID-19 Frozen
Dosage/Route	12 years of age and older -0.5 mL / IM (deltoid or vastus lateralis) 6 months of age to 11 years of age –0.25 mL/IM (deltoid or vastus lateralis)
Packaging	Multi-dose: Canadian packaging –2.5 mL vial
Diluent	No
Indication	Albertans 6 months of age and older See biological page for specific information.
Ingredients	<ul style="list-style-type: none"><li>• mRNA (new technology) –nucleoside-modified mRNA (modRNA) platform</li><li>• formulated in lipid nanoparticles (LNPs)</li><li>• no adjuvants, preservatives and antibiotics</li></ul>
Schedule	<b>5 years of age and older</b> <ul style="list-style-type: none"><li>• Not previously immunized or previously immunized–one dose</li></ul> <b>6 months to 4 years of age</b> <ul style="list-style-type: none"><li>• Not previously immunized–2 doses</li><li>• Previously immunized (1 or more previous doses) –one dose</li></ul> PLEASE SEE BIOLOGICAL PAGE FOR SPACING CONSIDERATIONS AND SCHEDULE FOR IMMUNOCOMPROMISED PERSONS.

# Moderna mRNA Vaccine Dosage and Schedule

## Individuals 5 years of age and older

- 1 dose, at least 3 months from a previous non-KP.2 COVID-19 vaccine dose, regardless of the number of doses received in the past.

## Dosage

- 5 to 11 years of age 0.25 mL
- 12 years of age and older 0.5 mL

# Moderna mRNA Vaccine Dosage and Schedule

## 6 months to 4 years of age

- Previously unimmunized:
  - Dose 1: day 0
  - Dose 2: at least 8 weeks after dose 1
- Previously immunized with one dose of a non-KP.2 COVID-19 vaccine series, regardless of product type:
  - 1 dose, at least 8 weeks from previous dose,
- Previously received two or more non-KP.2 COVID-19 vaccine doses, regardless of product type:
  - 1 dose, at least 3 months from previous dose

## Dosage

- 6 months to 4 years of age 0.25 mL



# Moderna mRNA Vaccine Dosage and Schedule

## Note:

Individuals 6 months to 4 years of age should complete a two-dose series of COVID-19 vaccine, regardless of the product that was administered for the first dose. The series should not be restarted.

# Moderna mRNA COVID-19 Vaccine Reactions

Common	<ul style="list-style-type: none"><li>• Pain, redness or swelling at injection site</li><li>• Chills, fever</li><li>• Fatigue</li><li>• Headache, myalgia, arthralgia</li><li>• Nausea, vomiting</li><li>• Axillary swelling or tenderness</li><li>• Dizziness</li><li>• Hypoaesthesia or paraesthesia</li><li>• In children under 5 years of age: irritability, crying, sleepiness, loss of appetite, otitis media</li></ul>
Rare	<ul style="list-style-type: none"><li>• Allergic reaction</li><li>• Anaphylaxis</li><li>• Erythema multiforme</li></ul>

# Moderna Storage and Preparation

- Store in freezer between  $-50^{\circ}\text{C}$  to  $-15^{\circ}\text{C}$ .
- Protect from light.
- Do not refreeze after thawing.

## Thawed, unpunctured:

- Thawed, unpunctured vials can be stored at  $+2^{\circ}\text{C}$  to  $+8^{\circ}\text{C}$  for up to 50 days.
- Thawed, unpunctured vials can be stored at  $+8^{\circ}\text{C}$  to  $+25^{\circ}\text{C}$  for up to 12 hours.

## Thawed, punctured vials:

- Thawed, punctured vials (first dose withdrawn) can be stored at  $+2^{\circ}\text{C}$  to  $+8^{\circ}\text{C}$  for 24 hours.
  - Discard after 24 hours.
- Thawed, punctured vials (first dose withdrawn) can be stored at room temperature up to  $+25^{\circ}\text{C}$  for 12 hours.
  - Discard after 12 hours.

# Moderna Storage and Preparation

Multidose vials are supplied as a frozen dispersion, does not contain preservative. Thaw vaccine before use:

- Vaccine can be thawed in two ways:
  - From the freezer to room temperature (between +15°C to +25°C), thaw for 45 minutes from frozen state.
  - From the freezer to a vaccine fridge (+2°C to +8°C), thaw for 2 hours from the frozen state.
- After thawing, let vial stand at room temperature for 15 minutes before administering.
- Must not be reconstituted, mixed with other medicinal product, or diluted.
- No dilution is required.
- Swirl gently after thawing and before each withdrawal.
- Do not shake vial.

# Pfizer mRNA COVID-19 Vaccine Summary

	Pfizer COVID-19 Ultra Frozen
Dosage/Route	12 years of age and older -0.3 mL (30 mcg) / IM (deltoid or vastus lateralis)
Packaging	Multi-dose: Canadian packaging –1.8 mL vial
Diluent	No
Indication	Albertans 12 years of age and older See biological page for specific information
Ingredients	<ul style="list-style-type: none"><li>• mRNA (new technology) –nucleoside-modified mRNA (modRNA) platform</li><li>• formulated in lipid nanoparticles (LNPs)</li><li>• no adjuvants, preservatives and antibiotics</li></ul>
Schedule	<b>12 years of age and older</b> <ul style="list-style-type: none"><li>• 1 dose, at least three months from previous non-KP.2 COVID-19 vaccine dose, regardless of the number of doses received in the past</li></ul> <p>PLEASE SEE BIOLOGICAL PAGE FOR SPACING CONSIDERATIONS AND SCHEDULE FOR IMMUNOCOMPROMISED PERSONS.</p>

# Pfizer mRNA Vaccine Dosage and Schedule

## Individuals 12 years of age and older

- 1 dose, at least three months from previous non-KP.2 COVID-19 vaccine dose, regardless of the number of doses received in the past.

## Dosage

- 12 years of age and older 0.3 mL

# Pfizer mRNA COVID-19 Vaccine Reactions

<b>Common</b>	<ul style="list-style-type: none"><li>• Pain, redness or swelling at injection site</li><li>• Chills, fever</li><li>• Fatigue</li><li>• Headache, myalgia, arthralgia</li><li>• Nausea, vomiting, diarrhea</li></ul>
<b>Uncommon</b>	<ul style="list-style-type: none"><li>• Lymphadenopathy</li><li>• Malaise, lethargy, dizziness</li><li>• Hypoesthesia, paresthesia, asthenia</li><li>• Decreased appetite</li><li>• Hyperhidrosis, night sweats</li></ul>
<b>Rare</b>	<ul style="list-style-type: none"><li>• Allergic reaction</li><li>• Anaphylaxis</li><li>• Facial swelling/Bell's Palsy*</li><li>• Myocarditis/Pericarditis*</li><li>• Erythema multiforme*</li></ul> <p>*There were no cases of facial swelling/Bell's Palsy, myocarditis/pericarditis and erythema multiforme following Pfizer Moderna XBB.1.5 immunization during the study period; however, these were reported post-market following Moderna (Original).</p>

# Pfizer Storage and Preparation

- Store in ultra low temperature freezer between -90°C to -60°C
- Protect from light until thawed
- Do not refreeze after thawing
- Thawed, unpunctured vials:
  - Thawed, unpunctured vials can be stored at +2°C to +8°C for up to 10 weeks
  - Thawed, unpunctured vials can be stored at +8°C to +25°C for up to 12 hours
    - Discard after 12 hours
- Thawed, punctured vials:
  - Thawed, punctured vials (first dose is withdrawn) can be stored at +2°C to +25°C for 12 hours.
  - Discard after 12 hours.

**Regardless of storage condition, the vaccine should not be used after the expiration date printed on the vials and cartons.**



# Pfizer Storage and Preparation

- Multidose vials are supplied as a frozen dispersion, does not contain preservative. Thaw vaccine before use.
- Vaccine can be thawed in two ways:
  - From the freezer to room temperature (between +15°C to +25°C), thaw for 30 minutes from frozen state.
  - From the freezer to a vaccine fridge (+2°C to +8°C), thaw for 6 hours from the frozen state.
- Must not be reconstituted, mixed with other medicinal product, or diluted.
- No dilution is required.
- Before use, mix the thawed vaccine by inverting the vial gently 10 times.
- Do not shake vial.

# Schedule for Individuals with Certain Immunocompromising Conditions

**Moderna – 6 months of age and older**

**Pfizer – 12 years of age and older**

Unimmunized/previously received fewer than 3 doses of COVID-19 vaccine

- Immunocompromised individuals should follow the schedule below and receive the appropriate number of doses of Moderna or Pfizer KP.2 COVID-19 vaccine to complete a three-dose COVID-19 vaccine series. Regardless of whether they have received one or two non-KP.2 COVID-19 vaccine doses, the previous dose(s) should be counted, and the series should not be restarted.
  - Dose 1: day 0
  - Dose 2: at least 28 days after dose 1
  - Dose 3: 8 weeks after dose 2; however, a minimum interval of 4 weeks may be considered.

# Schedule for Individuals with Certain Immunocompromising Conditions

Previously received 3 or more doses of a non KP.2 COVID-19 vaccine

- 1 dose, at least 3 months from previous COVID-19 vaccine dose, regardless of the number of doses received in the past.

Provide appropriate dose for age.

# Schedule for Individuals with Certain Immunocompromising Conditions

## Immunocompromising Conditions

- Specific immunocompromising conditions that make an individual eligible for a three dose COVID-19 vaccine series:
  - Solid organ transplant (SOT) recipients – pre-transplant and post-transplant.
  - Hematopoietic stem cell transplant (HSCT) recipients – pre-transplant and post-transplant while in an immunosuppressed state and individuals receiving Chimeric Antigen Receptor (CAR) T-Cell therapy. See:
    - Standard for Immunization of Transplant Candidates and Recipients
    - Immunization for Adult HSCT Transplant Recipients
    - Immunization for Child HSCT Transplant Recipients
  - Individuals with malignant hematologic disorders and non-hematologic malignant solid tumors prior to receiving or receiving active treatment which includes chemotherapy, targeted therapies, and immunotherapy or having received previous COVID-19 vaccines while on active treatment (does not include individuals receiving solely hormonal therapy, radiation therapy or a surgical intervention).

# Schedule for Individuals with Certain Immunocompromising Conditions

## Immunocompromised Individuals cont'd

- Individuals with chronic kidney disease on peritoneal dialysis or hemodialysis.
- Individuals on:
  - long term high-dose systemic steroid treatment (prednisone equivalent of equal to or greater than 2 mg/kg/day or 20 mg/day if weight greater than 10 kg, for 14 days or greater), or
  - alkylating agents, or
  - anti-B-cell therapies-including anti-CD19, anti-CD20, anti-CD22 and anti-CD52 monoclonal antibodies (such as rituximab, ocrelizumab, and ofatumumab), or
  - antimetabolites (e.g. methotrexate, azathioprine, mycophenolate), or
  - tumor-necrosis factor (TNF) inhibitors (e.g., adalimumab, certolizumab, etanercept, golimumab, infliximab), or
  - other agents that are significantly immunosuppressive at clinicians' discretion.

# Schedule for Individuals with Certain Immunocompromising Conditions

## Immunocompromised Individuals cont'd

- HIV-infected individuals without viral suppression or those with acquired immunodeficiency syndrome (AIDS).
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).

## Note:

- Documentation of immunocompromising conditions is not required. Individuals who identify themselves as meeting at least one of the criteria above should be offered the appropriate number of COVID-19 vaccine doses that an individual is eligible for.
- Immunization of immunocompromised individuals should occur at a time when the individual is most likely to mount an immune response. Physician consultation is recommended regarding the timing of immunization (initiation and interval) based on the individual's treatment and unique circumstances.

# COVID-19 Vaccine – Contraindications

COVID-19 vaccine should not be administered to individuals who:

- Have had an anaphylactic reaction to a previous dose of same COVID-19 vaccine
- Are less than licensed age for the product being used
- Have a known **type 1 hypersensitivity** to any component of the vaccine:
  - Tromethamine (trometamol or Tris) – component found in contrast media, oral and parenteral medications.
  - Polyethylene glycol (PEG). The potential allergen may be found in bowel preparation products for colonoscopy, laxatives, cough syrup, cosmetics, contact lens care solutions, skin products and some food and drinks.

# COVID-19 Vaccine – Precautions

- Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
- Administration should be postponed in individuals suffering from acute severe febrile illness.
- The safety and effectiveness of Pfizer-BioNTech KP.2 for individuals 6 months of age and older are inferred from studies which evaluated the primary series and booster vaccination with Pfizer-BioNTech and supported by studies which evaluated a booster dose of Pfizer-BioNTech Original & Omicron BA.4/BA.5 in individuals 6 months of age and older.

**NOTE:** Individuals who have had a serious allergic reaction to another vaccine, drug or food should talk to their health care provider before receiving the vaccine.



# COVID-19 Vaccine – Precautions

- Very rare cases of myocarditis and/or pericarditis following immunization with Moderna Spikevax or Pfizer Comirnaty or Novavax vaccines have been reported during post authorization use.
  - Compared to the original monovalent primary series, the risk of myocarditis and/or pericarditis is now expected to be lower due to the use of a 1-dose schedule in most individuals.
  - Post-market safety surveillance data on previous formulations of mRNA COVID-19 vaccine indicate that the risk of myocarditis following a booster dose is lower compared to that following the second dose in the primary series, and current data do not show a product-specific difference in the risks of myocarditis and/or pericarditis after a booster dose of an mRNA COVID-19 vaccine.
- Anyone receiving a COVID-19 vaccine should be informed of the risk of myocarditis and pericarditis and advised to seek medical attention if they develop related symptoms including shortness of breath, chest pain, or the feeling of a rapid or abnormal heart rhythm.

# COVID-19 Vaccine – Precautions

- Healthcare professionals are advised to consider the possibility of myocarditis and/or pericarditis in their differential diagnosis if individuals present with chest pain, shortness of breath, palpitations or other signs and symptoms of myocarditis and/or pericarditis following immunization with a COVID-19 vaccine.
- Generally, deferral of COVID-19 immunization is not required for those with a prior history of myocarditis or pericarditis that is unrelated to COVID-19 vaccines.
  - If these individuals have questions or concerns about their prior history of myocarditis or pericarditis and immunization, it is recommended that individuals consult with their clinician. However, consultation with a clinician is not required to receive COVID-19 vaccines.
- Individuals with a history compatible with pericarditis within 6 weeks of receiving a dose of a COVID-19 vaccine, who either had no cardiac workup or who had normal cardiac investigations, can be re-immunized when they are symptom free and at least 90 days have passed since previous immunization.
  - If another dose of vaccine is offered, it should be a Pfizer-BioNTech KP.2 COVID-19 vaccine, if 12 years of age and over. This is due to the lower reported rate of myocarditis and/or pericarditis following the Pfizer-BioNTech original (30 mcg) vaccine compared to the Moderna Spikevax original (100 mcg) vaccine among individuals 12 years of age and older.

# COVID-19 Vaccine – Precautions

- In most circumstances, further doses of COVID-19 vaccines should be deferred among people who experienced myocarditis (with or without pericarditis) within 6 weeks of receiving a previous dose of an COVID-19 vaccine.
  - However, further doses may be offered if individuals with confirmed myocarditis or pericarditis with abnormal cardiac investigation choose to receive another dose of vaccine after discussing the risks and benefits with their clinician.
  - Informed consent should discuss the unknown risk of recurrence of myocarditis and/or pericarditis following additional doses of COVID-19 vaccine in individuals with a history of confirmed myocarditis and/or pericarditis after a previous dose of COVID-19 vaccine.

# Pregnancy

- COVID-19 vaccine should be offered to pregnant individuals regardless of trimester of pregnancy because of the increased risk that infection poses in pregnancy. An mRNA vaccine is preferred due to reassuring published data on the safety of these vaccines in pregnancy.
- The safety and efficacy of Moderna Spikevax and Pfizer Comirnaty KP.2 in pregnant women has not yet been established.
- However, data available on the original mRNA vaccines administered in pregnancy did not detect safety signals from post-marketing surveillance. COVID-19 vaccines can be offered to pregnant individuals as they are more at risk for severe illness from COVID-19 compared with non-pregnant individuals.
  - It is recommended that individuals consult with their primary health care provider or medical specialist for any vaccine related questions or concerns.
  - However, consultation with a primary health care provider or medical specialist is not required to receive COVID-19 vaccine.

# Pregnancy

## COVID-19 mRNA Vaccine use in Pregnancy and Newborn and Early Infant Outcomes

Study done in Ontario, Canada, using multiple linked health administration databases, singleton births with estimated dates of delivery from May 1, 2021, to September 2, 2022, in which the mother received at least one mRNA COVID vaccine while pregnant.

- 142 006 infants included in the study, 85 670 were exposed to 1 or more COVID-19 vaccine doses in utero
- Infants of vaccinated mothers had lower risks of severe neonatal morbidity, neonatal death and NICU admission compared with no maternal COVID-19 vaccination before delivery
- No association between maternal vaccination in pregnancy and neonatal readmission or 6-month hospital admission
- Maternal mRNA COVID-19 vaccination during pregnancy was not associated with increased adverse newborn and early infant outcomes and may be protective against adverse newborn outcomes.

Jorgensen SCJ, Drover SSM, Fell DB, et al. Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy. *JAMA Pediatr*. Published online October 23, 2023. doi:10.1001/jamapediatrics.2023.4499

# Breastfeeding

- It is unknown whether COVID-19 vaccine is excreted in human milk as breastfeeding individuals were excluded from the initial trials. A risk to the newborns/infants cannot be excluded.
- Recent reports have shown that breastfeeding people who have received mRNA COVID-19 vaccines have antibodies in their breastmilk, which could help protect their babies. More data are needed to determine the level of protection these antibodies might provide to the baby.
- COVID-19 vaccine is recommended for individuals who are breastfeeding
  - It is recommended that individuals consult with their primary health care provider or medical specialist for any vaccine related questions or concerns.
  - However, consultation with a primary health care provider or medical specialist is not required to receive COVID-19 vaccine.

# Co-administration with other vaccines

- For co-administration with other vaccines, refer to the “Administration With Other Products” section in the relevant COVID-19 vaccine biological page.

# Commitment to Comfort

## Needle Fears

- This can affect people to a degree that they avoid immunization

Commitment to Comfort | Alberta Health Services outlines five principles to improve the immunization experience, health outcomes, satisfaction and encourage repeat attendance to healthcare encounters.

- Make a comfort plan
- Use positive language
- Use comfort positions
- Shift attention
- Use numbing cream



## AEFI reporting

Any of the following are also reportable adverse events:

- GBS
- ORS
- Anaphylaxis
- Other allergic reactions
- Any reaction outside of what is expected

Consult with AHS Adverse Event Following Immunization (AEFI) Team at [AEFI@ahs.ca](mailto:AEFI@ahs.ca) or 1-855-444-2324 as soon as possible for any case where there is uncertainty as to whether a symptom following immunization is related to the immunization.

Severe reactions (anaphylaxis and death) should be reported within 24 hours and all other reactions within 3 days to the AEFI Team. “Reportable AEFIs” are reported to Alberta Health, and in turn to the National Surveillance Program.

## AEFI Reporting

An adverse event following immunization is defined as a serious or unexpected event temporally associated with immunization.

Local reactions are the most reported event following immunization. A local reaction of pain and/or swelling is **ONLY** reportable if:

1. the onset of swelling is within 48 hours following immunization;

**AND**

2. swelling extends past the nearest joint

**OR**

3. severe pain that interferes with the normal use of the limb lasting greater than 4 days

**OR**

4. reaction requires hospitalization

# Anaphylaxis

Alberta Health Services employees need to ensure they have completed the Anaphylaxis Management | Insite ([albertahealthservices.ca](http://albertahealthservices.ca)) learning module.

Covenant Health employees need to ensure they have completed Covenant Health Anaphylaxis Learning Module found on CLiC.

All other providers must have Anaphylaxis Management Guidelines in place.

- Additional information available in the Canadian Immunization Guide – Vaccine Safety

# Infection Prevention and Control (IPC)

IPC's mandate is to reduce the incidence of healthcare associated infections in patients, residents, and clients by:

- process and outcome surveillance
- outbreak identification and management
- consultation and education
- guideline, policy, and procedure development
- Research

For more information go to the AHS IPC website at:

<https://www.albertahealthservices.ca/info/page6410.aspx>

## References

Alberta Health. (2024 September). Alberta Vaccine Storage and Handling for COVID-19 Vaccine. In *Alberta Immunization Policy: Cold chain storage and handling*. Government of Alberta.

Alberta Health. (2024 October). COVID-19 Vaccine mRNA-Moderna Spikevax KP.2. In *Alberta Immunization Policy: Biological Products*. Government of Alberta.

Alberta Health. (2024 October ). COVID-19 Vaccine -mRNA Pfizer-BioNTech Comirnaty KP.2. In *Alberta Immunization Policy: Biological Products*. Government of Alberta.

BioNTech Manufacturing GmbH. Comirnaty Omicron KP.2. Product Monograph, (2024). Available from: <https://covid-vaccine.canada.ca/info/pdf/comirnaty-kp2-pm-en.pdf>

Centers for Disease Control and Prevention. COVID-19 Vaccines while pregnant or breastfeeding [Internet]. COVID-19. 2023. Available from: [COVID-19 Vaccination for People Who Are Pregnant or Breastfeeding | COVID-19 | CDC](#)

Expert opinion of Alberta Advisory Committee on Immunization. (September 20, 2023: January 18, 2024).

Moderna Biopharma Canada Corp. SPIKEVAX KP.2 (COVID-19 mRNA vaccine). Product Monograph, (2024). Available from: <https://covid-vaccine.canada.ca/info/pdf/comirnaty-kp2-pm-en.pdf>

## References

National Advisory Committee on Immunization. *Guidance on the use of COVID-19 vaccines during the fall of 2024*. Public Health Agency of Canada

National Advisory Committee on Immunization. *Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19 2023*. Public Health Agency of Canada.

Shimabukuro, T., Kim, S., et al. *Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons*. The New England Journal of Medicine. (2021 April 21) Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104983>

# QUESTIONS & THANKS

Email [CDCIMM@ahs.ca](mailto:CDCIMM@ahs.ca) or call 1-855-444-2324